Pfizer shares droop on Goldman downgrade; Mylan, Abbott settle fight over Depakote

> Already trading at their lowest levels in more than a decade, shares of Pfizer Inc. slipped in premarket trading Thursday after a Goldman Sachs analyst cut his rating on the drug maker's stock. Report

> Mylan and Abbott Laboratories have settled their patent fight over Depakote ER; the deal allows Mylan 180-day exclusivity on 500 mg tablets to be launched before January 1, 2009 and gives the generics maker a license for the 250 mg strength, too. Report

> Johnson & Johnson expects its $16.6 billion acquisition of Pfizer Consumer Health to break even or increase earnings modestly by 2009, a year earlier than previously expected. Report

> Novartis spent nearly $1.3 million lobbying the U.S. government in the first quarter on drug and health care issues. Report

> The University of Pittsburgh Medical Center might have the nation's strictest policies barring gifts and travel from the pharmaceutical industry, a recent study found. Report

> Researchers say they can cheaply and easily track how effective some cancer drugs are at cutting off a tumor's blood supply by using a technique called bioluminescence imaging. Report

And Finally ... Indonesia says it's going to keep bird-flu deaths quiet because publicizing them just makes the country look bad. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.